Evaluation of a New Skeletal Troponin I Assay in Patients with Idiopathic Inflammatory Myopathies.

Autor: Bamberg K; Department of Biochemistry/Biotechnology, University of Turku, Turku, Finland., Mehtälä L; Department of Biochemistry/Biotechnology, University of Turku, Turku, Finland., Arola O; Intensive Care Medicine and Pain Management, Turku University Hospital, Turku, Finland., Laitinen S; Regional Laboratory NordLab Kajaani, Kajaani, Finland., Nordling P; Heart Center, Turku University Hospital, Turku, Finland., Strandberg M; Heart Center, Turku University Hospital, Turku, Finland., Strandberg N; Department of Orthopaedic Surgery, Turku University Hospital, Turku, Finland., Paltta J; Department of Rheumatology, Turku University Hospital, Turku, Finland., Mali M; Department of Rheumatology, Turku University Hospital, Turku, Finland., Espinosa-Ortega F; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden., Pirilä L; Department of Rheumatology, Turku University Hospital, Turku, Finland., Lundberg IE; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden., Savukoski T; Department of Biochemistry/Biotechnology, University of Turku, Turku, Finland., Pettersson K; Department of Biochemistry/Biotechnology, University of Turku, Turku, Finland.
Jazyk: angličtina
Zdroj: The journal of applied laboratory medicine [J Appl Lab Med] 2020 Mar 01; Vol. 5 (2), pp. 320-331.
DOI: 10.1093/jalm/jfz016
Abstrakt: Background: The current biomarkers for diagnosis and monitoring of injured and diseased skeletal muscles, such as creatine kinase (CK), have limited tissue specificity and incapability to differentiate between pathological and physiological changes. Thus, new biomarkers with improved diagnostic accuracy are needed. Our aim was to develop and validate a novel assay for skeletal troponin I (skTnI), and to assess its clinical performance in patients with idiopathic inflammatory myopathies (IIM).
Methods: A two-step fluoroimmunoassay was used to analyze samples from healthy reference individuals (n = 140), patients with trauma (n = 151), and patients with IIM (n = 61).
Results: The limit of detection was 1.2 ng/mL, and the upper reference limit (90th percentile) was 5.2 ng/mL. The median skTnI concentrations were Conclusions: With the skTnI assay, patients with IIM were identified from healthy individuals and from patients with traumatic muscular injuries. When compared to CK, skTnI appeared to be more accurate in managing patients with low-grade IIM disease activities. The developed assay serves as a reliable analytical tool for the assessment of diagnostic accuracy of skTnI in the diagnosis and monitoring of myopathies.
(© American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze: MEDLINE
Externí odkaz: